Biodesix Validates Thermo Fisher's Oncomine Dx Express Test for Solid Tumors on Genexus Dx Integrated Sequencer.
PorAinvest
martes, 19 de agosto de 2025, 9:49 am ET1 min de lectura
BDSX--
The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This achievement underscores Biodesix's role in the development and validation of diagnostic tools crucial for cancer research and treatment [2].
Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care. The company's collaboration with Thermo Fisher is part of a broader initiative to advance NGS-based diagnostics and precision medicine [1].
Scott Hutton, CEO at Biodesix, expressed his excitement about the designation, stating, "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future" [1].
Upcoming presentations will provide more information on the Thermo Fisher NGS precision oncology solution and Biodesix's application of this technology for industry clients and healthcare professionals [1].
References:
[1] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html
[2] https://www.globenewswire.com/news-release/2025/08/19/3135801/0/en/Biodesix-Recognized-as-a-Thermo-Fisher-Scientific-Center-of-Excellence-COE-for-NGS-Diagnostics.html
TMO--
Biodesix has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This designation reflects Biodesix's expertise in molecular diagnostics and NGS testing capabilities. Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care.
Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. This designation reflects Biodesix's expertise in molecular diagnostics and NGS testing capabilities [1].The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This achievement underscores Biodesix's role in the development and validation of diagnostic tools crucial for cancer research and treatment [2].
Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care. The company's collaboration with Thermo Fisher is part of a broader initiative to advance NGS-based diagnostics and precision medicine [1].
Scott Hutton, CEO at Biodesix, expressed his excitement about the designation, stating, "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future" [1].
Upcoming presentations will provide more information on the Thermo Fisher NGS precision oncology solution and Biodesix's application of this technology for industry clients and healthcare professionals [1].
References:
[1] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html
[2] https://www.globenewswire.com/news-release/2025/08/19/3135801/0/en/Biodesix-Recognized-as-a-Thermo-Fisher-Scientific-Center-of-Excellence-COE-for-NGS-Diagnostics.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios